325770-44-3Relevant academic research and scientific papers
Novel inhibitor of p38 MAP kinase as an anti-TNF-α drug: Discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent
Miwatashi, Seiji,Arikawa, Yasuyoshi,Kotani, Etsuo,Miyamoto, Maki,Naruo, Ken-Ichi,Kimura, Hiroyuki,Tanaka, Toshimasa,Asahi, Satoru,Ohkawa, Shigenori
, p. 5966 - 5979 (2007/10/03)
The p38 mitogen-activated protein (MAP) kinase has been implicated in the proinflammatory cytokine signal pathway, and its inhibitors are potentially useful for the treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and inflammat
MEDICINAL COMPOSITIONS
-
, (2008/06/13)
The present invention relates to an agent for the prophylaxis or treatment of pain, an agent for suppressing activation of osteoclast, and an inhibitor of osteoclast formation, which contains a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor.
Substituted 1,3-thiazole compounds, their production and use
-
, (2008/06/13)
(1) A 1,3-thiazole compound of which the 5-position is substituted with a 4-pyridyl group having a substituent including no aromatic group or (2) a 1,3-thiazole compound of which the 5-position is substituted with a pyridyl group having at the position adjacent to a nitrogen atom of the pyridyl group a substituent including no aromatic group has an excellent p38 MAP kinase inhibitory activity.
